The U.S. Food and Drug Administration (FDA) granted initial approval to Orforglipron, known by its brand name Foundayo, on April 1, 2026. This approval designates Orforglipron as a new molecular entity (NME) developed by Eli Lilly and Co., marking a significant regulatory milestone.
Background
Orforglipron, also identified as Foundayo, is classified by the FDA as a Type 1 - New Molecular Entity. This classification indicates that the drug product contains an active ingredient that has not been previously approved by the agency. The development and sponsorship of Orforglipron were undertaken by Eli Lilly and Co.
What this means
The initial FDA approval of Orforglipron (Foundayo) on April 1, 2026, introduces a novel therapeutic option to the market. As a new molecular entity, Orforglipron represents a unique chemical structure and mechanism of action, distinct from existing approved drugs. This regulatory step enables Eli Lilly and Co. to make Foundayo available to patients, potentially addressing unmet medical needs within its intended, though currently unspecified, indication. Clinicians and healthcare providers will now have access to this new compound as a potential treatment strategy.
Source
The information regarding the initial FDA approval of Foundayo (orforglipron) was obtained from the U.S. Food and Drug Administration (FDA) database. The approval details, including the event date of April 1, 2026, are publicly accessible via accessdata.fda.gov.